Tumor immunologists were first concerned with the question of whether or not tumors possess tumor-specific antigens. Now they ask why autochthonous and syngeneic tumors, possessing tumor-specific transplantation antigens, are not rejected by their hosts as homografts, and they seek to uncover mechanisms by which tumors escape destruction by the immune system.
Over the years much evidence has accumulated linking immunodeficiency and cancer, a subject recently reviewed by Kersey et al. (1) . This association suggests the possibility that tumors may escape from host immune surveillance by subverting the immune system directly. We now have direct evidence, presented here, that syngeneic mouse tumors, both chemical and virus-induced, are indeed immunosuppressive. Additional evidence was published recently by Wong et al. (2) , who showed that interaction in vitro between tumor cells and spleen cells caused the spleen cells to become immunologically unresponsive, and by Fauve et al. (3) , who reported that tumors repulse macrophages in vitro and inhibit the inflammatory reaction in vio.
It seems, therefore, that subversion of the immune system by tumors could be a viable escape mechanism for tumors. However, unless we know the mechanism of this subversion and how to control it, we cannot hope to use immunotherapy effectively in treating cancer. Starting with the clue that tumor cells tend to produce excessive amounts of prostaglandins (4-6), we * Four days after administration of sRBC, mice were first bled to obtain serum and then sacrificed to obtain the spleen. Sera were assayed for hemagglutinating antibody; the titer is expressed as log2 of dilution end-point. Spleens were assayed for antibody-forming cells, measured as plaque-forming cells. these mice were tested for immunological responsiveness to sRBC, injected intravenously. In all cases, they were examined for antibody response 4 days after injection of sRBC. The sera from these mice were assayed for hemagglutinating antibody, and their spleens were assayed for plaque-forming cells. The results, given in Table 1 , show that by day 4, tumor-bearing mice were already significantly immunodeficient and, by day 6, essentially unresponsive to sRBC.
In a similar experiment, 106 syngeneic MIC-16 tumor cells were inoculated into groups of C57B1/6J mice. This number of cells sufficed to establish a tumor that was generally palpable in about 1 week and that grew progressively until death of the animals in about 4 weeks. At intervals of 5 days, starting from the time tumor cells were inoculated, groups of these mice were tested for immunological responsiveness to sRBC. Instead of injecting the sRBC directly into the animals and measuring the antibody response in vivo, as in the previous experiment, the sRB3C were added to suspensions of spleen cells from the test animals and cultured in vitro for 4 days, after which the cultures were examined for plaque-forming .5 cells. In each instance, spleens of normal mice served as controls. The tumor-bearers were almost completely immunosuppressed by day 10 as is clearly shown in Table 2 and judging from its rate of development, immunodeficiency had probably started on about day 5.
Immunosuppression by tumor cells in vitro (10) . However, low concentrations of tumor cells were less immunosuppressive in the presence of indomethacin (Fig. 2) . Aspirin, which also inhibits prostaglandin synthetases, gave 8 similar results (data not shown), and provides further evidence for involvement of prostaglandins in immunosuppression by tumor cells.
Because indomethacin blocked immunosuppression by tumor cells in vitro, it was also tested for its possible effect on tumor development in vivo. Groups of C57B1/6J mice were inoculated with syngeneic MVC-16 tumor, and treatment with indomethacin was started on the day of tumor inoculation. The control group was given diluent, and two experimental groups were given indomethacin, one for 10 days and the other for 14 days. The rate of tumor growth was significantly reduced as a result of indomethacin treatment, but it was not arrested even when the period of treatment was extended beyond 10 days into the period of increased rate of tumor growth (Fig. 3) We also have evidence that tumor cells need to be viable and metabolically active in order to be immunosuppressive (10) , and there have-been reports that certain tumor cell lines produce excessive amounts of the prostaglandin PGE2 (4) (5) (6) and the PGE2 stimulates endogenous adenosine 3':5'-cyclic monolhosphate (cAMP) in spleen cells (11 
